Johnson & Johnson’s Kenvue valued at around $41 billion in IPO

By Julia Wray | Published: 4-May-2023

The health care giant’s new consumer health arm priced above the middle of the expected range ahead of trading on the New York Stock Exchange

Johnson & Johnson’s Kenvue consumer health business has been valued at around US$41bn in its initial public offering.

The company announced it will list 172,812,560 shares at a price of $22 per share, slightly above the middle of its price range.

Read more:

Johnson & Johnson readies IPO for Kenvue consumer health business

It had earlier announced its intention to sell shares at a range between $20 and $23 per share.

The stock will begin trading on the New York Stock Exchange under the symbol KVUE today.

J&J will continue to own more than 90% of Kenvue’s shares.

The deal is said to be the largest IPO pan-industry to launch since electric vehicle maker Rivian Automotive listed its shares on Nasdaq in late 2021.

  • Companies:
  • Johnson and Johnson
See more

You may also like

Finance

J&J’s $260 million talc lawsuit verdict overturned

Read more
Oregon resident Kyung Lee won the litigation against J&J in June 2024, but the verdict has now been overturned with a new trial date to be set

Trending Articles

  1. Expect matcha, rice milk and sesame in fragrance launches in 2025 A report curated by The Fragrance Shop and CPL Aromas also said to expect the rise of technology and personalisation in fragrance in the new year
  2. Chanel N°5 unveils new campaign starring Margot Robbie and Jacob Elordi Margot Robbie succeeds Marion Cotillard as the new face of fragrance
  3. Justmylook Celebrates 10th Anniversary with a Night of Beauty and Celebration Leading online beauty retailer Justmylook marked its 10th anniversary last Thursday with a glamorous evening celebrating a decade of success
  4. Lush accused of exploiting freelance workers during Christmas rush Flexi work apps promoted by TikTok influencers are being alleged to lack basic employment rights
  5. Junior Production & Product Development Coordinator - London - £25-30,000 (AE670526) Do you have a knack for project management and an organised nature?

Upcoming event

Launch Lab: Future-Forward Cosmetics – Beyond Packaging 2025 - WEBINAR

17 January 2025 See all

You may also like

Finance

J&J’s $260 million talc lawsuit verdict overturned

Oregon resident Kyung Lee won the litigation against J&J in June 2024, but the verdict has now been overturned with a new trial date to be set
Regulatory

New J&J talc lawsuit first to seek medical monitoring for cancer

The proposed class action is the first to seek medical monitoring, or regular testing for female talc users to catch cancer early
You need to be a subscriber to read this article.
Click here to find out more.
Skin Care

J&J recalls Clean & Clear Facial Cleansers in the US due to micro contamination

An FDA enforcement report notice states the company is voluntarily recalling at wholesale level 7,800 bottles of Clean & Clear’s Morning Burst Facial Cleanser
Skin Care

Neutrogena signs Olympic gold medalist Sydney McLaughlin-Levrone as ambassador

The US track star will represent the skin care brand alongside existing ambassadors Jenna Ortega and Chloe and Halle Bailey
Skin Care

J&J to hold 9.5% stake in consumer health spinoff Kenvue following share exchange

The multinational launched the exchange offer in July in a bid to take its hands off the Kenvue reins
Regulatory

Johnson & Johnson to appeal $19 million owed to California cancer patient

The talc cancer trial involving 24-year-old Emory Hernandez Valadez was the first faced by J&J since its bankruptcy filing
You need to be a subscriber to read this article.
Click here to find out more.
Colour Cosmetics

Metaverse Beauty Week day 4 review - madcap mushrooms and nonsensical buildings shadow over potential

The Cosmetics Business editorial team will be reviewing each day of Metaverse Beauty Week 2023, 12-17 June
Subscribe now